Tissue Engineering and Regenerative Medicine

, Volume 13, Issue 5, pp 455–464 | Cite as

The therapeutic potential of stem cells and progenitor cells for the treatment of Parkinson’s disease

  • Mooi Tiong Liau
  • Farahnaz Amini
  • Thamil Selvee Ramasamy
Feature Article Cell Biology
First Online:
Received:
Revised:
Accepted:

Abstract

Parkinson’s disease (PD) is the second most common neurodegenerative disorder. It is usually seen in those above 50 years old. Current medical treatments only provide symptomatic relief but cannot cure the disease. There are claims that PD can be cured by stem cell transplant. The present study is aimed to assess the clinical potency and safety of stem cell in treating PD. A total of eleven articles were included for analysis, with four randomised control trials (RCTs), five non-RCTs and 2 follow up studies. All the four non-RCTs showed improvement of Unified Parkinson’s Disease Rating Scale with no adverse events. However, results from RCTs showed no significant differences in the rating score among the transplant group and the Sham surgery group. The secondary analysis of one study showed a significant improvement of the rating score in those patients aged 60 and younger. Transplant group also associated with an overall higher incidence of adverse events. In conclusion, the RCTs and non-RCTs produced opposite results. When the studies were performed as non-RCTs in small number of patients, they showed promising result in the patients. It could say that currently the use of stem cell/progenitor cells in treating PD need much research despite having the implanted stem cell to be able to survive and integrated. The survival of implanted dopamine neurons in the striatum, however, does not indicate a success in correcting PD symptoms. Further investigations will shed light on the application and mechanism of action of stem cells in treating PD.

Key Words

Neurodegenerative disease Cell therapy Stem cell transplantation Neuro-regeneration and neuroprotection 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Supplementary material

13770_2016_9093_MOESM1_ESM.pdf (32 kb)
Supplementary material, approximately 32 KB.

References

  1. 1.
    Gale E, Li M. Midbrain dopaminergic neuron fate specification:of mice and embryonic stem cells. Mol Brain 2008;1:8.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Kumar P, Clark M. Clinical Medicine:a text book for medical students and doctors. 3rd ed. London:Bailliere Tindal;1994.Google Scholar
  3. 3.
    Parkinson’s Disease. [Internet] 2012 May [cited 2013 July 13]. Available from:http://www.stemcellnetwork.ca/en/diseases/parkinsons-disease/.Google Scholar
  4. 4.
    Tan LC, Venketasubramanian N, Jamora RD, Heng D. Incidence of Parkinson’s disease in Singapore. Parkinsonism Relat Disord 2007;13:40–43.CrossRefPubMedGoogle Scholar
  5. 5.
    Chew NK, Goh KJ, Tan CT. Parkinson’s disease in university hospital, Kuala Lumpur. Neurol J Southeast Asia 1998;3:75–80.Google Scholar
  6. 6.
    Lim SY, Ibrahim NM, Puvanarajah SD, Lee MK, Yoon CK, Viswanathan S, et al. 2012 consensus guidelines for the treatment of Parkinson’s disease. Malaysia:Movement Disorders Council;2012.Google Scholar
  7. 7.
    Schapira AH. Etiology of Parkinson’s disease. Neurology 2006;66(10 Suppl 4):S10–S23.CrossRefPubMedGoogle Scholar
  8. 8.
    Lesage S, Brice A. Parkinson’s disease:from monogenic forms to genetic susceptibility factors. Hum Mol Genet 2009;18:R48–R59.CrossRefPubMedGoogle Scholar
  9. 9.
    Khan NL, Jain S, Lynch JM, Pavese N, Abou-Sleiman P, Holton JL, et al. Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson’s disease:clinical, pathological, olfactory and functional imaging and genetic data. Brain 2005;128:2786–2796.CrossRefPubMedGoogle Scholar
  10. 10.
    Rajput AH, Uitti RJ, Stern W, Laverty W, O’Donnell K, O’Donnell D, et al. Geography, drinking water chemistry, pesticides and herbicides and the etiology of Parkinson’s disease. Can J Neurol Sci 1987;14(3 Suppl):414–418.CrossRefPubMedGoogle Scholar
  11. 11.
    Jankovic J. Complications and limitations of drug therapy for Parkinson’s disease. Neurology 2000;55(12 Suppl 6):S2–S6.PubMedGoogle Scholar
  12. 12.
    Kofman OS. Complications of therapy in Parkinson’s disease. Can Fam Physician 1983;29:87–91.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Nishimura K, Takahashi J. Therapeutic application of stem cell technology toward the treatment of Parkinson’s disease. Biol Pharm Bull 2013;36:171–175.CrossRefPubMedGoogle Scholar
  14. 14.
    Olanow CW, Goetz CG, Kordower JH, Stoessl AJ, Sossi V, Brin MF, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson’s disease. Ann Neurol 2003;54:403–414.CrossRefPubMedGoogle Scholar
  15. 15.
    Xue Y, Li X, Pang S, Wang Y, Yao J, Zhou J, et al. Efficacy and safety of computer-assisted stereotactic transplantation of human retinal pigment epithelium cells in the treatment of Parkinson disease. J Comput Assist Tomogr 2013;37:333–337.CrossRefPubMedGoogle Scholar
  16. 16.
    Trott CT, Fahn S, Greene P, Dillon S, Winfield H, Winfield L, et al. Cognition following bilateral implants of embryonic dopamine neurons in PD:a double blind study. Neurology 2003;60:1938–1943.CrossRefPubMedGoogle Scholar
  17. 17.
    Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R, et al. Transplantation of embryonic dopamine neurons for severe Parkinson’s disease. N Engl J Med 2001;344:710–719.CrossRefPubMedGoogle Scholar
  18. 18.
    Stover NP, Bakay RA, Subramanian T, Raiser CD, Cornfeldt ML, Schweikert AW, et al. Intrastriatal implantation of human retinal pigment epithelial cells attached to microcarriers in advanced Parkinson disease. Arch Neurol 2005;62:1833–1837.CrossRefPubMedGoogle Scholar
  19. 19.
    Venkataramana NK, Kumar SK, Balaraju S, Radhakrishnan RC, Bansal A, Dixit A, et al. Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinson’s disease. Transl Res 2010;155:62–70.CrossRefPubMedGoogle Scholar
  20. 20.
    Venkataramana NK, Pal R, Rao SA, Naik AL, Jan M, Nair R, et al. Bilateral transplantation of allogenic adult human bone marrow-derived mesenchymal stem cells into the subventricular zone of Parkinson’s disease:a pilot clinical study. Stem Cells Int 2012;2012:931902.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Yin F, Tian ZM, Liu S, Zhao QJ, Wang RM, Shen L, et al. Transplantation of human retinal pigment epithelium cells in the treatment for Parkinson disease. CNS Neurosci Ther 2012;18:1012–1020.CrossRefPubMedGoogle Scholar
  22. 22.
    Gross RE, Watts RL, Hauser RA, Bakay RA, Reichmann H, von Kummer R, et al. Intrastriatal transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson’s disease:a double-blind, randomised, controlled trial. Lancet Neurol 2011;10:509–519.CrossRefPubMedGoogle Scholar
  23. 23.
    Kordower JH, Freeman TB, Chen EY, Mufson EJ, Sanberg PR, Hauser RA, et al. Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson’s disease. Mov Disord 1998;13:383–393.CrossRefPubMedGoogle Scholar
  24. 24.
    Kordower JH, Chu Y, Hauser RA, Olanow CW, Freeman TB. Transplanted dopaminergic neurons develop PD pathologic changes:a second case report. Mov Disord 2008;23:2303–2306.CrossRefPubMedGoogle Scholar
  25. 25.
    Srijaya TC, Ramasamy TS, Kasim NH. Advancing stem cell therapy from bench to bedside:lessons from drug therapies. J Transl Med 2014;12:243.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Noisa P, Ramasamy TS, Lamont FR, Yu JS, Sheldon MJ, Russell A, et al. Identification and characterisation of the early differentiating cells in neural differentiation of human embryonic stem cells. PLoS One 2012;7:e37129.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Kefalopoulou Z, Politis M, Piccini P, Mencacci N, Bhatia K, Jahanshahi M, et al. Long-term clinical outcome of fetal cell transplantation for Parkinson disease:two case reports. JAMA Neurol 2014;71:83–87.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Hallett PJ, Cooper O, Sadi D, Robertson H, Mendez I, Isacson O. Longterm health of dopaminergic neuron transplants in Parkinson’s disease patients. Cell Rep 2014;7:1755–1761.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© The Korean Tissue Engineering and Regenerative Medicine Society and Springer Science+Business Media Dordrecht 2016

Authors and Affiliations

  • Mooi Tiong Liau
    • 1
  • Farahnaz Amini
    • 1
  • Thamil Selvee Ramasamy
    • 2
  1. 1.School of Healthy Aging, Medical Aesthetics and Regenerative Medicine, Faculty of Medicine and Health ScienceUCSI UniversityKuala LumpurMalaysia
  2. 2.Department of Molecular MedicineFaculty of Medicine, University of MalayaKuala LumpurMalaysia

Personalised recommendations